| ADA | Anti-Drug Antibody |
| ADC | Antibody-Drug Conjugate |
| AST | Aspartate Aminotransferase |
| BCMA | B-Cell Maturation Antigen |
| BSA | Body Surface Area |
| CM | Compartment Model |
| CL | Clearance |
| CrCL | Creatinine Clearance |
| DAR | Drug-to-Antibody Ratio |
| ECD | Extracellular Domain |
| ECOG | Eastern Cooperative Oncology Group |
| F | Bioavailability |
| FcRn | Neonatal Fc Receptor |
| FDA | Food and Drug Administration |
| mAb | Monoclonal Antibody |
| MMAE | Monomethyl Auristatin E |
| MMAF | Monomethyl Auristatin F |
| PBPK | Physiologically Based Pharmacokinetics |
| PD | Pharmacodynamics |
| PK | Pharmacokinetics |
| PopPK | Population Pharmacokinetics |
| SC | Subcutaneous |
| TAb | Total Antibody |
| tADC | Total Antibody-Drug Conjugate |
| TDCL | Time-Dependent Clearance |
| T-DM1 | Trastuzumab Emtansine |
| T-Dxd | Trastuzumab Deruxtecan |
| TMDD | Target-Mediated Drug Disposition |
| T-vc-MMAE | Trastuzumab-MMAE |
| Vss | Volume of Distribution |